TVTXTravere Therapeutics, Inc.

$3B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45M+8.2% YoY

Gross Profit

$44M97.8% margin

Operating Income

-$37M-81.7% margin

Net Income

-$39M-86.6% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

+13.0%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$22M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$648M

Total Liabilities

$370M

Stockholders' Equity

$277M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$41M	+8.2%
Gross Profit	$44M	$40M	+8.9%
Operating Income	-$37M	-$22M	-69.4%
Net Income	-$39M	-$22M	-73.3%

Revenue Segments

Thiola License

$24M53%

Bile Acid Products

$21M47%

TVTX Q2 2019 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena